Shares of Nymox Pharmaceuticals took a beating after the company announced that an FDA panel had rejected its kit for detecting Alzheimer's. By a 5-2 vote the panel asked for more data on verification and clarification of test results. CEO Paul Averback said in a statement that he was anticipating working with the FDA on gaining more data. Report